Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Common Equity: 2016-2025

Historic Common Equity for Anaptysbio (ANAB) over the last 9 years, with Sep 2025 value amounting to -$29.4 million.

  • Anaptysbio's Common Equity fell 134.87% to -$29.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$29.4 million, marking a year-over-year decrease of 134.87%. This contributed to the annual value of $70.9 million for FY2024, which is 19.56% down from last year.
  • Per Anaptysbio's latest filing, its Common Equity stood at -$29.4 million for Q3 2025, which was up 34.24% from -$44.7 million recorded in Q2 2025.
  • In the past 5 years, Anaptysbio's Common Equity registered a high of $385.7 million during Q2 2021, and its lowest value of -$44.7 million during Q2 2025.
  • Its 3-year average for Common Equity is $65.5 million, with a median of $70.9 million in 2024.
  • Its Common Equity has fluctuated over the past 5 years, first rose by 6.49% in 2021, then crashed by 552.81% in 2025.
  • Over the past 5 years, Anaptysbio's Common Equity (Quarterly) stood at $356.4 million in 2021, then declined by 26.46% to $262.1 million in 2022, then slumped by 66.39% to $88.1 million in 2023, then decreased by 19.56% to $70.9 million in 2024, then slumped by 134.87% to -$29.4 million in 2025.
  • Its Common Equity was -$29.4 million in Q3 2025, compared to -$44.7 million in Q2 2025 and $34.0 million in Q1 2025.